256 filings
8-K
ALT
Altimmune Inc
27 Mar 24
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
7:04am
8-K
ALT
Altimmune Inc
30 Nov 23
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
4:28pm
8-K
ALT
Altimmune Inc
7 Nov 23
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
7:06am
8-K
ALT
Altimmune Inc
28 Sep 23
Submission of Matters to a Vote of Security Holders
4:55pm
8-K
ALT
Altimmune Inc
10 Aug 23
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
7:04am
8-K
0kbn7i2kni3zk
11 May 23
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
7:03am
8-K
bbggq4a55yqs2lybg
27 Mar 23
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
4:06pm
8-K
89g 3z4shjbqx3t
21 Mar 23
Regulation FD Disclosure
7:04am
8-K
7p15b94xx dzeqt5i
28 Feb 23
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
7:04am
8-K
6nlgo3jpqm5nm0k
20 Dec 22
Regulation FD Disclosure
7:05am
8-K
qcm egulmxoi5ee
10 Nov 22
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update
7:06am
8-K
3uwsq94ewpj3 6cpsl
29 Sep 22
Submission of Matters to a Vote of Security Holders
4:07pm
8-K
hlph1utxik5vh2nny
14 Sep 22
Regulation FD Disclosure
7:13am
8-K
b3csf
11 Aug 22
Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update
7:09am
8-K
x4mnj 7gkwh4q0e
12 May 22
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
7:07am
8-K
d2jjrnn2i24la5quwt0u
15 Mar 22
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
7:07am
8-K
ixvhbxasos
17 Dec 21
Termination of a Material Definitive Agreement
5:15pm
8-K
d6rqpvhgh q9pe
13 Dec 21
Altimmune Appoints Richard Eisenstadt as Chief Financial Officer
6:30am
8-K
ufwe kgagz
9 Nov 21
Altimmune Announces Third Quarter 2021 Financial Results
4:08pm
8-K
3ovwiy l4
28 Sep 21
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of
7:10am